Company Update (NASDAQ:RMTI): Rockwell Medical Inc to Present at Stifel 2015 Healthcare Conference
Rockwell Medical Inc (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, announced today that it will present at the Stifel 2015 Healthcare Conference being held at The New York Palace Hotel, New York, NY, November 17-18, 2015. Management will present an overview of the Company, including their innovative iron maintenance therapy drug Triferic, the only FDA approved iron product indicated to replace iron and maintain hemoglobin in hemodialysis patients inthe United States.
|Stifel Health Care Conference Details:
||Wednesday, November 18, 2015
||11:45 AM Eastern Time
||Hubbard at The New York Palace Hotel, New York, NY
||Rob Chioini, Founder and Chief Executive Officer (Original Source)
Shares of Rockwell Medical closed yesterday at $10.62. RMTI has a 1-year high of $18.90 and a 1-year low of $7.09. The stock’s 50-day moving average is $10.17 and its 200-day moving average is $12.19.
On the ratings front, Rockwell Medical has been the subject of a number of recent research reports. In a report issued on November 10, Oppenheimer analyst Ling Wang maintained a Buy rating on RMTI, with a price target of $26, which implies an upside of 144.8% from current levels. Separately, on the same day, Brean Murray Carret’s Jonathan Aschoff reiterated a Sell rating on the stock and has a price target of $4.
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Ling Wang and Jonathan Aschoff have a total average return of -5.1% and -3.1% respectively. Wang has a success rate of 34.9% and is ranked #3470 out of 3840 analysts, while Aschoff has a success rate of 41.5% and is ranked #3581.
Rockwell Medical Inc is a biopharmaceutical company targeting end-stage renal disease and chronic kidney disease with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis.